Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abvc Biopharma (ABVC) Deferred Taxes (2018 - 2023)

Historic Deferred Taxes for Abvc Biopharma (ABVC) over the last 6 years, with Q4 2023 value amounting to $151387.0.

  • Abvc Biopharma's Deferred Taxes fell 8310.51% to $151387.0 in Q4 2023 from the same period last year, while for Dec 2023 it was $1.1 million, marking a year-over-year increase of 2359.97%. This contributed to the annual value of $115668.0 for FY2023, which is 8662.49% down from last year.
  • Abvc Biopharma's Deferred Taxes amounted to $151387.0 in Q4 2023, which was down 8310.51% from -$117414.0 recorded in Q3 2023.
  • Abvc Biopharma's 5-year Deferred Taxes high stood at $896049.0 for Q4 2022, and its period low was -$117414.0 during Q3 2023.
  • In the last 5 years, Abvc Biopharma's Deferred Taxes had a median value of -$40568.0 in 2020 and averaged $83475.4.
  • In the last 5 years, Abvc Biopharma's Deferred Taxes plummeted by 20799.17% in 2020 and then skyrocketed by 75676.13% in 2021.
  • Abvc Biopharma's Deferred Taxes (Quarter) stood at -$28054.0 in 2019, then crashed by 207.99% to -$86404.0 in 2020, then soared by 756.76% to $567468.0 in 2021, then soared by 57.9% to $896049.0 in 2022, then tumbled by 83.11% to $151387.0 in 2023.
  • Its last three reported values are $151387.0 in Q4 2023, -$117414.0 for Q3 2023, and $896049.0 during Q4 2022.